Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Current Assets: 2012-2025

Historic Current Assets for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to $204.3 million.

  • Enanta Pharmaceuticals' Current Assets fell 31.85% to $204.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $204.3 million, marking a year-over-year decrease of 31.85%. This contributed to the annual value of $204.3 million for FY2025, which is 31.85% down from last year.
  • As of FY2025, Enanta Pharmaceuticals' Current Assets stood at $204.3 million, which was down 31.85% from $299.9 million recorded in FY2024.
  • Over the past 5 years, Enanta Pharmaceuticals' Current Assets peaked at $422.8 million during FY2023, and registered a low of $204.3 million during FY2025.
  • Its 3-year average for Current Assets is $309.0 million, with a median of $299.9 million in 2024.
  • Its Current Assets has fluctuated over the past 5 years, first soared by 35.63% in 2023, then slumped by 31.85% in 2025.
  • Yearly analysis of 5 years shows Enanta Pharmaceuticals' Current Assets stood at $319.0 million in 2021, then fell by 2.29% to $311.7 million in 2022, then spiked by 35.63% to $422.8 million in 2023, then dropped by 29.08% to $299.9 million in 2024, then tumbled by 31.85% to $204.3 million in 2025.